Seres Therapeutics

United States
Primghar, Iowa, United States, 02139

Company profile

Seres Therapeutics company profile

Seres Therapeutics develops and delivers therapies composed of live bacterial consortia that aim to modulate the human gut microbiome for therapeutic benefit. The company’s platform draws on insights into microbial ecology, host immune function, and gut barrier integrity to create oral treatments that act via multiple biological pathways. Its pipeline includes products designed to prevent infectious complications and antimicrobial-resistant bloodstream infections in vulnerable patient populations, as well as treatments for inflammatory and immune-related gastrointestinal disorders. Seres translates microbiome research into clinical development, manufacture, and commercialization of these novel live biotherapeutic medicines.

Business identity

Contact email
[email protected]
Phone number
+1 617 945 9626
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$10M-$100M
Founded
2010-01-01, Year

Headquarters

Postal code
02139
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
11
Total equity funding
$422.2M
Last funding
Grant / $3.6M / 2025-10-29
Last equity funding
Post IPO Equity
Investors
9
Lead investors
4
Founders
2
Articles
209
Exited on
2015-06-26

Founders and investors

Founders

Geoffrey von MaltzahnNoubar Afeyan

Lead investors

CARB-XFlagship PioneeringNestlé Health ScienceOaktree Capital Management

Investors

Flagship PioneeringMayo ClinicOaktree Capital ManagementRA Capital ManagementSofinnova Investments